Compare Summit Therapeutics Inc (SMMT) vs SpaceX (SPCX) Price & Performance

Summit Therapeutics IncTrade

SpaceXTrade

Price performance (Past 24H)

Key statistics

Summit Therapeutics Inc vs SpaceX — how do they compare? Summit Therapeutics Inc trades at $17.54 (market cap $13.71B), while SpaceX trades at $162.53 (market cap $2.18T). The key difference: SpaceX is far larger — about 159× Summit Therapeutics Inc's market cap, and SpaceX is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and SpaceX for 41 Days on average.

	SMMT	SPCX
Market Cap	$13.71B	$2.18T
Volume	6,173,057	68,508,567
Sector	Health	Industrials
52-Week High	$26.38	$202.09
52-Week Low	$12.43	$108.27
Typical Hold Time	16 Days	41 Days
Enterprise Value	$13.04B	$2.12T

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.

SpaceX

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SMMT

No sentiment data available yet.

SPCX

54% Buy46% Sell

Avg holding period · 41 Days

Top news

Latest headlines on both assets

SMMT

AstraZeneca invests $2B in Summit Therapeutics to advance next-gen cancer drug ivonescimab.CNBC · 4 days agoBullish View details →

SPCX

AST SpaceMobile shares drop 6% as SpaceX secures low-band spectrum, tightening competition for satellite phone links.24/7 Wall Street · 10 hours agoBearish SpaceX's Starlink expands mobile service, pressuring AT&T, Verizon, and T-Mobile shares.Proactive Investors · 10 hours agoBearish SpaceX rises 4% after buying nationwide low-band spectrum, pressuring Verizon and AT&T stocks down 7%.24/7 Wall Street · 11 hours agoNeutral View details →

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

About SpaceX

SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.